Unicycive Therapeutics, Inc

UNCYNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

27.9M

on 2026-06-30, from 3.76M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-10 reverse split; each bar's tip shows the count as filed.

Newest

$150.0M

S-3 of 2026-06-05. None sold under it to 2026-10-05. S-3 ↗

$100.0M

Guggenheim Securities, agreement of 2025-11-14. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-12 is not read yet.

Cash

8.8 quarters

$61.4M on 2026-06-30 ÷ $7.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 6 of its filings are not read yet.

Also on file: a 1-for-10 reverse split, 2025-06-17 8-K ↗